Immune Defects in Alzheimer's Disease and New Medication Development
Author Information
Author(s): Cashman John R, Ghirmai Senait, Abel Kenneth J, Fiala Milan
Primary Institution: Human BioMolecular Research Institute, San Diego, CA, USA
Hypothesis
Can bisdemethoxycurcumin enhance phagocytosis and clearance of amyloid-beta in Alzheimer's disease patients?
Conclusion
Bisdemethoxycurcumin enhances immune function in mononuclear cells of Alzheimer's disease patients and may provide a novel approach to immunotherapy.
Supporting Evidence
- Mononuclear cells from Alzheimer's disease patients generally display defective phagocytosis.
- Bisdemethoxycurcumin was shown to enhance Aβ phagocytosis and increase MGAT3 and TLR gene expression.
- Control subjects' macrophages efficiently transport Aβ, unlike those from Alzheimer's patients.
Takeaway
This study found that a natural compound from turmeric can help the immune cells of Alzheimer's patients clear harmful proteins from the brain better.
Methodology
The study involved examining the effects of bisdemethoxycurcumin on phagocytosis and gene expression in mononuclear cells from Alzheimer's disease patients.
Potential Biases
Potential bias due to the small sample size and the specific population studied.
Limitations
The study may not account for all genetic variations affecting Aβ clearance in different individuals.
Participant Demographics
Participants included 42 control subjects and 73 Alzheimer's disease patients.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website